Ruben Mesa, M.D., Chair of Hematology and Oncology at Mayo Clinic in Arizona, discusses common patient questions regarding myeloproliferative neoplasms with John Camoriano, M.D., medical oncology consultant at Mayo Clinic.
Ruben Mesa, M.D., hematologist and Deputy Director of the Mayo Clinic Cancer Center in Arizona, provides his top ten recommendations for battling the fatigue associated with a diagnosis of myeloproliferative neoplasm.
Diagnosis of MDS or MDS/MPN must begin with morphology (analysis of the form and structure of patient blood or bone marrow cells). When used alone, today’s advanced techniques to study genes and chromosomes don’t give enough information to find out what type of MDS or MDS/MPN a patient has.
Conventional cytogenetics is a method to analyze chromosomes. Researchers and clinicians use conventional cytogenetics to diagnose blood disorders, predict outcomes in patients with these disorders, and develop new treatments that target genetic changes associated with a disease.
Bridging the Overlap Gap: Understanding the Natural History of Myelodysplastic/ Myeloproliferative Neoplasm (MDS/MPN)
Different types of MDS/MPN have similar symptoms but profoundly different outcomes. The type and intensity of treatment must be tailored to each patient’s type of MDS/MPN. Therefore, it is important to diagnose these diseases accurately.